Market Cap 148.90B
Revenue (ttm) 24.57B
Net Income (ttm) 3.61B
EPS (ttm) N/A
PE Ratio 26.08
Forward PE 24.84
Profit Margin 14.71%
Debt to Equity Ratio 0.48
Volume 5,164,000
Avg Vol 4,839,654
Day's Range N/A - N/A
Shares Out 702.99M
Stochastic %K 98%
Beta 0.78
Analysts Strong Sell
Price Target $225.71

Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell cultu...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 202 828 0850
Fax: 202 828 0860
Address:
2200 Pennsylvania Avenue N.W., Suite 800W, Washington, United States
Equibles
Equibles Sep. 20 at 8:19 PM
$DHR Equibles has it in the filing data. Across T. Rowe Price Investment Management, Inc.'s last two Form 13F filings, most recently filed August 14, 2026, its DHR position rose 82.8% to 6,919,744 split-adjusted shares by June 30, 2026, an estimated $1.32 billion.
0 · Reply
Quant_Builder
Quant_Builder Sep. 18 at 1:40 PM
$QQQ $SPY $SMTC $DHR $MU quant-builder.ai Got The Relief Rally We got the relief rally. Rates look like they have stabilized for the moment, and oil is somewhat stable as well. Yesterday I gained about 1.5% on the day. INTC, MU, and SNDK were big winners among a few others. I am completely out of INTC now. KLAC popped on the open and the platform automatically sold one third. I still own two thirds. By the middle of the day, I was only 35% long, so I opened up my Discretionary Model and added some of those picks. We are looking at 'lower' rates, lower oil and we may get a nice bounce from the sector. I only added 1% to 10 separate picks. Some well-known names like, JACK, HOG, NCLH and KMX. Top holdings this morning are pretty boring. DHR, AAPL, BIO, KLAC, AMGN, and TEAM. I am only 45% invested, down from 70% yesterday. Sticking to the strategy of staying between 40-70% long and rotating among stocks in the models. First image is this morning, September 18. Combined top picks sorted by confidence. New ticker, SMTC is number one. It has broken out to all-time highs. A lot of familiar names still on the board. Second image is the combined portfolio chart. Three models, top 20 at the open, buy the open, -5% stop, held through the target date. Which is the main 3 models I have been trading. Third image is the account. Similar returns and path as the models show. Free demo at quant-builder.ai/learn
0 · Reply
TradeQuant
TradeQuant Sep. 17 at 3:55 PM
$DHR Entering long. 1/15/2027 $250. Options flow.
0 · Reply
HMaxxx0920
HMaxxx0920 Sep. 17 at 3:32 PM
$DHR $250 Calls JAN 2027 $3 Million
0 · Reply
SunriseTrader
SunriseTrader Sep. 15 at 4:35 PM
$DHR making a nice move today. A close over 209.50 what I am watching to get me to move up stops. Updated chart
1 · Reply
Constraintalphacom
Constraintalphacom Sep. 15 at 8:34 AM
AI biotech’s biggest developments aren’t just better models anymore. The real shift is happening down the stack: → Owkin + Servier: AI + proprietary multimodal patient data → Thermo Fisher + NVIDIA: AI-connected autonomous labs → Benchling/TetraScience: connecting instruments, data & agents → BioNeMo: becoming scientific AI middleware → Self-driving labs: moving from demos toward real workflows Meanwhile, the ultimate proof is still missing at scale: repeatable clinical success from AI-discovered drugs. The bottleneck has moved from compute → models → experimental validation. That’s why the picks-and-shovels may matter most: $TMO, $DHR, $RGEN, Tecan, Sartorius + scientific data infrastructure. Models are becoming abundant. Experimental truth is still scarce.
0 · Reply
Invest2575
Invest2575 Sep. 14 at 9:32 PM
$DHR What happened?
1 · Reply
SunriseTrader
SunriseTrader Sep. 14 at 4:58 PM
$DHR with a test of the 200ema and bounce, follow thru today.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 9 at 6:11 PM
$DHR Really good write-up that perfectly summarizes DHR's present situation. So if you want to bring your DHR knowledge up to date or just discover DHR, this is required reading. https://everyticker.com/quote/DHR/analysis/danaher-s-dbs-powered-transformation-why-masimo-integration-and-bioprocessing-timing-create-a-compelling-risk-reward-nyse-dhr
0 · Reply
11thestate
11thestate Sep. 9 at 12:44 PM
The $172.5M Danaher Corporation ($DHR) deadline is in 11 days (September 20) If you bought shares between 2022 and 2023, you may be eligible for the $172.5M recovery fund. The settlement resolves claims that Danaher misled investors about its bioprocessing business and COVID-related demand. The company repeatedly cut its outlook as demand weakened, and investors later filed a lawsuit. File your claim here: https://11th.com/cases/danaher-investor-settlement
0 · Reply
Latest News on DHR
Danaher Announces Quarterly Dividend

Sep 15, 2026, 4:15 PM EDT - 6 days ago

Danaher Announces Quarterly Dividend

DHR


Don't Quit on Danaher Stock After Horrific Earnings Reaction

Jul 22, 2026, 5:06 AM EDT - 2 months ago

Don't Quit on Danaher Stock After Horrific Earnings Reaction

DHR


Danaher Earnings Call Transcript: Q2 2026

Jul 21, 2026, 8:00 AM EDT - 2 months ago

Danaher Earnings Call Transcript: Q2 2026


Danaher Quarterly report: Q2 2026

Jul 21, 2026, 8:00 AM EDT - 2 months ago

Danaher Quarterly report: Q2 2026


Danaher Earnings release: Q2 2026

Jul 21, 2026, 8:00 AM EDT - 2 months ago

Danaher Earnings release: Q2 2026


Danaher Slides: Q2 2026

Jul 21, 2026, 8:00 AM EDT - 2 months ago

Danaher Slides: Q2 2026


Danaher Reports Second Quarter 2026 Results

Jul 21, 2026, 6:00 AM EDT - 2 months ago

Danaher Reports Second Quarter 2026 Results

DHR


The Big 3: JPM, DHR, MRK

Jun 25, 2026, 1:00 PM EDT - 2 months ago

The Big 3: JPM, DHR, MRK

DHR JPM MRK


Danaher Schedules Second Quarter 2026 Earnings Conference Call

Jun 22, 2026, 4:15 PM EDT - 3 months ago

Danaher Schedules Second Quarter 2026 Earnings Conference Call

DHR


The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 3 months ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX


Danaher Completes Acquisition of Masimo Corporation

Jun 10, 2026, 8:55 AM EDT - 3 months ago

Danaher Completes Acquisition of Masimo Corporation

DHR


Sirius XM Holdings Set to Join S&P MidCap 400

Jun 8, 2026, 6:09 PM EDT - 3 months ago

Sirius XM Holdings Set to Join S&P MidCap 400

DHR SPGI


Danaher Transcript: AGM 2026

May 5, 2026, 3:00 PM EDT - 4 months ago

Danaher Transcript: AGM 2026


Masimo Shareholders Approve Acquisition by Danaher

May 4, 2026, 9:00 AM EDT - 4 months ago

Masimo Shareholders Approve Acquisition by Danaher

DHR MASI


Danaher Earnings Call Transcript: Q1 2026

Apr 21, 2026, 8:00 AM EDT - 5 months ago

Danaher Earnings Call Transcript: Q1 2026


Danaher Earnings release: Q1 2026

Apr 21, 2026, 8:00 AM EDT - 5 months ago

Danaher Earnings release: Q1 2026


Danaher Quarterly report: Q1 2026

Apr 21, 2026, 8:00 AM EDT - 5 months ago

Danaher Quarterly report: Q1 2026


Danaher Slides: Q1 2026

Apr 21, 2026, 8:00 AM EDT - 5 months ago

Danaher Slides: Q1 2026


Danaher Reports First Quarter 2026 Results

Apr 21, 2026, 6:00 AM EDT - 5 months ago

Danaher Reports First Quarter 2026 Results

DHR


Danaher Proxy statement: Proxy filing

Mar 25, 2026, 8:00 AM EDT - 6 months ago

Danaher Proxy statement: Proxy filing


Danaher Proxy statement: Proxy filing

Mar 25, 2026, 8:00 AM EDT - 6 months ago

Danaher Proxy statement: Proxy filing


Danaher Schedules First Quarter 2026 Earnings Conference Call

Mar 20, 2026, 4:15 PM EDT - 6 months ago

Danaher Schedules First Quarter 2026 Earnings Conference Call

DHR


Danaher Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:50 PM EST - 6 months ago

Danaher Transcript: TD Cowen 46th Annual Health Care Conference


Danaher Slides: Corporate presentation

Feb 26, 2026, 7:00 AM EST - 6 months ago

Danaher Slides: Corporate presentation


Danaher to Present at TD Cowen Health Care Conference

Feb 24, 2026, 4:05 PM EST - 6 months ago

Danaher to Present at TD Cowen Health Care Conference

DHR


Danaher to buy Masimo for $9.9 billion

Feb 17, 2026, 8:04 AM EST - 7 months ago

Danaher to buy Masimo for $9.9 billion

DHR MASI


Masimo to be Acquired by Danaher for $180.00 Per Share

Feb 17, 2026, 8:02 AM EST - 7 months ago

Masimo to be Acquired by Danaher for $180.00 Per Share

DHR MASI


Danaher To Acquire Masimo Corporation

Feb 17, 2026, 8:00 AM EST - 7 months ago

Danaher To Acquire Masimo Corporation

DHR MASI


Danaher Strikes $10 Billion Deal for Masimo

Feb 17, 2026, 6:09 AM EST - 7 months ago

Danaher Strikes $10 Billion Deal for Masimo

DHR MASI


Danaher Earnings Call Transcript: Q4 2025

Jan 28, 2026, 8:00 AM EST - 7 months ago

Danaher Earnings Call Transcript: Q4 2025


Danaher Annual report: Q4 2025

Jan 28, 2026, 8:00 AM EST - 7 months ago

Danaher Annual report: Q4 2025


Danaher Earnings release: Q4 2025

Jan 28, 2026, 8:00 AM EST - 7 months ago

Danaher Earnings release: Q4 2025


Danaher Slides: Q4 2025

Jan 28, 2026, 8:00 AM EST - 7 months ago

Danaher Slides: Q4 2025


Danaher Reports Fourth Quarter and Full Year 2025 Results

Jan 28, 2026, 6:00 AM EST - 7 months ago

Danaher Reports Fourth Quarter and Full Year 2025 Results

DHR


Danaher Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 2:15 PM EST - 8 months ago

Danaher Slides: 44th Annual J.P. Morgan Healthcare Conference


Danaher CEO to Comment on Financial Performance

Jan 12, 2026, 9:00 AM EST - 8 months ago

Danaher CEO to Comment on Financial Performance

DHR


The Big 3: BA, DHR, DG

Jan 8, 2026, 1:05 PM EST - 8 months ago

The Big 3: BA, DHR, DG

BA DG DHR


Danaher Is Ready to Put Its Post-Covid Malaise Behind It

Jan 8, 2026, 8:00 AM EST - 8 months ago

Danaher Is Ready to Put Its Post-Covid Malaise Behind It

DHR


Danaher to Present at J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:15 PM EST - 8 months ago

Danaher to Present at J.P. Morgan Healthcare Conference

DHR


Danaher Schedules Fourth Quarter 2025 Earnings Conference Call

Dec 17, 2025, 7:30 AM EST - 9 months ago

Danaher Schedules Fourth Quarter 2025 Earnings Conference Call

DHR


3 More Good Stocks to Invest In After Earnings

Nov 18, 2025, 4:29 PM EST - 10 months ago

3 More Good Stocks to Invest In After Earnings

DHR FTNT LPLA


Danaher Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 6:00 AM EST - 10 months ago

Danaher Transcript: Jefferies London Healthcare Conference 2025


The Big 3: TMO, DHR, VLO

Nov 13, 2025, 12:50 PM EST - 10 months ago

The Big 3: TMO, DHR, VLO

DHR TMO VLO


Danaher to Present at Jefferies Global Healthcare Conference

Nov 11, 2025, 4:15 PM EST - 10 months ago

Danaher to Present at Jefferies Global Healthcare Conference

DHR


Danaher Earnings Call Transcript: Q3 2025

Oct 21, 2025, 8:00 AM EDT - 11 months ago

Danaher Earnings Call Transcript: Q3 2025


Danaher Quarterly report: Q3 2025

Oct 21, 2025, 8:00 AM EDT - 11 months ago

Danaher Quarterly report: Q3 2025


Danaher Earnings release: Q3 2025

Oct 21, 2025, 8:00 AM EDT - 11 months ago

Danaher Earnings release: Q3 2025


Danaher Slides: Q3 2025

Oct 21, 2025, 8:00 AM EDT - 11 months ago

Danaher Slides: Q3 2025


Equibles
Equibles Sep. 20 at 8:19 PM
$DHR Equibles has it in the filing data. Across T. Rowe Price Investment Management, Inc.'s last two Form 13F filings, most recently filed August 14, 2026, its DHR position rose 82.8% to 6,919,744 split-adjusted shares by June 30, 2026, an estimated $1.32 billion.
0 · Reply
Quant_Builder
Quant_Builder Sep. 18 at 1:40 PM
$QQQ $SPY $SMTC $DHR $MU quant-builder.ai Got The Relief Rally We got the relief rally. Rates look like they have stabilized for the moment, and oil is somewhat stable as well. Yesterday I gained about 1.5% on the day. INTC, MU, and SNDK were big winners among a few others. I am completely out of INTC now. KLAC popped on the open and the platform automatically sold one third. I still own two thirds. By the middle of the day, I was only 35% long, so I opened up my Discretionary Model and added some of those picks. We are looking at 'lower' rates, lower oil and we may get a nice bounce from the sector. I only added 1% to 10 separate picks. Some well-known names like, JACK, HOG, NCLH and KMX. Top holdings this morning are pretty boring. DHR, AAPL, BIO, KLAC, AMGN, and TEAM. I am only 45% invested, down from 70% yesterday. Sticking to the strategy of staying between 40-70% long and rotating among stocks in the models. First image is this morning, September 18. Combined top picks sorted by confidence. New ticker, SMTC is number one. It has broken out to all-time highs. A lot of familiar names still on the board. Second image is the combined portfolio chart. Three models, top 20 at the open, buy the open, -5% stop, held through the target date. Which is the main 3 models I have been trading. Third image is the account. Similar returns and path as the models show. Free demo at quant-builder.ai/learn
0 · Reply
TradeQuant
TradeQuant Sep. 17 at 3:55 PM
$DHR Entering long. 1/15/2027 $250. Options flow.
0 · Reply
HMaxxx0920
HMaxxx0920 Sep. 17 at 3:32 PM
$DHR $250 Calls JAN 2027 $3 Million
0 · Reply
SunriseTrader
SunriseTrader Sep. 15 at 4:35 PM
$DHR making a nice move today. A close over 209.50 what I am watching to get me to move up stops. Updated chart
1 · Reply
Constraintalphacom
Constraintalphacom Sep. 15 at 8:34 AM
AI biotech’s biggest developments aren’t just better models anymore. The real shift is happening down the stack: → Owkin + Servier: AI + proprietary multimodal patient data → Thermo Fisher + NVIDIA: AI-connected autonomous labs → Benchling/TetraScience: connecting instruments, data & agents → BioNeMo: becoming scientific AI middleware → Self-driving labs: moving from demos toward real workflows Meanwhile, the ultimate proof is still missing at scale: repeatable clinical success from AI-discovered drugs. The bottleneck has moved from compute → models → experimental validation. That’s why the picks-and-shovels may matter most: $TMO, $DHR, $RGEN, Tecan, Sartorius + scientific data infrastructure. Models are becoming abundant. Experimental truth is still scarce.
0 · Reply
Invest2575
Invest2575 Sep. 14 at 9:32 PM
$DHR What happened?
1 · Reply
SunriseTrader
SunriseTrader Sep. 14 at 4:58 PM
$DHR with a test of the 200ema and bounce, follow thru today.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 9 at 6:11 PM
$DHR Really good write-up that perfectly summarizes DHR's present situation. So if you want to bring your DHR knowledge up to date or just discover DHR, this is required reading. https://everyticker.com/quote/DHR/analysis/danaher-s-dbs-powered-transformation-why-masimo-integration-and-bioprocessing-timing-create-a-compelling-risk-reward-nyse-dhr
0 · Reply
11thestate
11thestate Sep. 9 at 12:44 PM
The $172.5M Danaher Corporation ($DHR) deadline is in 11 days (September 20) If you bought shares between 2022 and 2023, you may be eligible for the $172.5M recovery fund. The settlement resolves claims that Danaher misled investors about its bioprocessing business and COVID-related demand. The company repeatedly cut its outlook as demand weakened, and investors later filed a lawsuit. File your claim here: https://11th.com/cases/danaher-investor-settlement
0 · Reply
DonCorleone77
DonCorleone77 Sep. 9 at 10:57 AM
$DHR Danaher assumed with a Buy at UBS UBS assumed coverage of Danaher with a Buy rating and $250 price target. Danaher's latest bioprocessing setback has tested investor patience, but the selloff creates an attractive risk/reward as bioprocessing recovers, Life Sciences reaccelerates, and Diagnostics gains momentum under incoming CEO Julie Sawyer Montgomery, potentially driving organic growth back to low-single digits this year and mid-single digits next year, the analyst tells investors in a research note.
0 · Reply
1manfund
1manfund Sep. 7 at 6:24 AM
Synthetic DNA for training data sets in AI led Drug Discovery : Twist Bioscience $TWST, Azenta $AZTA, DNA Script, GenScript, Danaher $DHR, Illumina $ILMN
0 · Reply
onlythebestcompanies
onlythebestcompanies Sep. 7 at 5:29 AM
$DHR $280 soon.
0 · Reply
IN0V8
IN0V8 Sep. 1 at 4:31 PM
$DHR Buying Opportunity HSBC raises target price to $250 from $230
0 · Reply
onlythebestcompanies
onlythebestcompanies Aug. 31 at 1:20 PM
$DHR $280 soon.
0 · Reply
Quant_Builder
Quant_Builder Aug. 27 at 1:48 PM
$TMO $QQQ $IYH $TEAM $DHR quant-builder.ai NVDA Earnings Behind Us, Jackson Hole Tomorrow NVDA looking like it's good enough for the market. Doesn't seem like the market is responding quite like it used to. So just going to add to the dips. TMO is my top holding still and it actually trimmed a little yesterday, it hit a take-profit but still the top holding. I have some more exits coming up and then I let some stretch. Just going to add to the stocks in the model on dips. I am going to add to tech as well. The QQQ had some nice consolidation above 700, earnings behind us, the only real thing left is the interest rates and the Fed. The first image is Today's Picks from those three models. Combined list, ranked by confidence. 33 deduplicated picks, avg confidence 72.3% of the top 20. TMO at the top then TEAM, MU, RKLB, STX, DHR. Tech is on the page through Tech 100 and QB500: TEAM, MU, RKLB, STX. The second image is a history of those models combined. Had you just opened Today's Picks every day and bought the top 20 at 1% per position at the opening price, used a -5% stop, and held through the target date, this is how it would perform. 46% win rate, +0.33% average hold return, and the model path is up about 10.39%. The Third Image is my account. It tracks pretty closely to the models that I use. Which makes sense, I only trade the stocks on the lists. However, I don't do as the model does and just buy the top 20 everyday on the open.
0 · Reply
spql8r
spql8r Aug. 25 at 6:27 PM
$AMFN During my working years with $LH and $DGX, we deal with companies like $BDX and $DHR, which have a ton of patents. I remember LabCorp one day when it was looking to buy a lab in Tustin, CA. When I researched the lab, it did not have much volume. What's interesting is it has a lot of patents. The big 2 labs usually buy the lab because they have the volume, because volume equals revenue. So patents are important. AMFN is preparing for the future with revenues from the patents or exclusivity. In the lab business, they usually pay 5x the revenue. I know, it's less than the multiplier in other fields since it's 10 to 30 times more. What we have here—commercialization of Texatron, a fusion engine soon to power up data centers—is unique. Rarity also has a multiplier. Take a look, NFA. DYODD.😎 5737👀
0 · Reply
11thestate
11thestate Aug. 25 at 12:49 PM
Don't forget that there is also an important settlement to watch for $DHR We have every detail, including how investors can get paid: https://11th.com/cases/danaher-investor-settlement
0 · Reply
Form4Alerts
Form4Alerts Aug. 25 at 2:24 AM
$DHR — President & CEO Rainer Blair sold $12.7M · Chief executive selling their own company. · Largest sale they've ever made in it. · Sold into a +22% month. Insider grade: C (from their own prior trades) Not investment advice.
0 · Reply
onlythebestcompanies
onlythebestcompanies Aug. 24 at 5:17 PM
$DHR $280 soon.
0 · Reply
Quant_Builder
Quant_Builder Aug. 24 at 12:49 PM
$TMO $IYH $SPY $RSP $DHR quant-builder.ai Story is kinda the same. Buying solid dips over the next few weeks. The interest rate volatility might cause some sharp pullbacks, but we could get a ripping rally on any good news on rates. So, I'm going to nibble on each dip, try and get a little more invested, and trade the stocks in the models. For today at least I am dropping the Tech model I have been using, although I will want to get involved. I have my QB500 and Healthcare models pulled up. Ranked. There are actually a few tech names on here from the QB500 model so that's good enough. Healthcare still has high confidence and lots of picks, with TMO as the top pick, and it's on the verge of breaking out from a long-held resistance level. I own some, keeping some take profit takes tight in case it fails as well as a trailing stop. Good earnings, the Iran war is a known unknown, everything else we know. Inflation is sticky, the Fed may have to raise rates, the rates have been adjusting for that, jobs okay, and still an insane amount of infrastructure investment over the next 6-12 months. There really is no new economic news, just headline news and interest rate volatility. The first image is Today's Picks from those two models. Combined list, ranked by confidence. 41 deduplicated picks. TMO at the top then DHR, BIO, SYK. Tech is still on the page through QB500: SMCI, MU, ASTS. The second image is a history of these two models combined. Had you just opened Today's Picks every day and bought the top 20 at 1% per position at the opening price, used a −5% stop, and held through the target date, this is how it would perform. I don't do that exactly. I nibble, I skip names, I take profits etc. But, I do not just cherry pick one name and oversize it. Trade in batches with proper positions sizes.
0 · Reply
CapitalMonk
CapitalMonk Aug. 22 at 1:58 AM
$DHR Price: $218.85 (+1.36%) Trend: Bearish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.53% RSI: 72.8 | Momentum: Moderate Volume: -6.4% vs avg Volatility: 1.90% Support: $189.85 | Resistance: $220.67 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply